June 6, 2023Recently, Beilu Pharmaceutical received the "Drug Supplement Application Approval Notice" (Notice No.: 2023B02662) for repaglinide tablets issued by the National Medical Products Administrat...view
May 13, 2021For the purpose of medical imaging, a certain substance is introduced into the human body to change the image contrast of the body's local tissues.view
January 23, 2024Recently, Beilu Pharmaceutical's independently developed exclusive pure Chinese medicine formulation, Jiuwei Zhenxin granules, has been included in the "Double Heart Outpatient Construction S...view
April 2, 2025Recently, Hichi Pharmaceutical's iopamidol API received the "Approval Notice for the Marketing Application of Chemical APIs" from the National Medical Products Administration. This is an...view
February 24, 2023Recently, the "Wealth and Responsibility - Values of Enterprises" 2022 China Top 500 Charity List Conference was held in Chongqing. Since its inclusion in 2021, Beilu Pharmaceutical has been...view
April 12, 2021On March 11th, the National Medical Products Administration (NMPA) issued the “Notice Recognizing Excellent Units in the National Adverse Drug Reactions Monitoring and Evaluation 2020”.view